ANDREW SCHIFF

Andrew Schiff stands as a distinguished Managing Partner at Aisling Capital, a leading private equity firm renowned for its strategic investments in the dynamic life sciences industry. Since joining Aisling Capital in 2000, Mr. Schiff has played a pivotal role in shaping the firm's investment strategy and portfolio, leveraging his unique blend of medical expertise and financial acumen.

Aisling Capital, under the leadership of partners like Mr. Schiff, is committed to fostering innovation across the healthcare landscape. The firm's investment focus spans a broad spectrum of the life sciences, including groundbreaking biotechnology companies, pharmaceutical enterprises developing novel therapies, advanced medical device manufacturers, and diagnostic innovators. Mr. Schiff's deep understanding of clinical development, regulatory pathways, and market dynamics allows him to identify companies with high growth potential and significant impact on patient care. He actively engages with portfolio companies, providing strategic guidance to help them navigate complex challenges and achieve their commercial objectives.

Prior to his tenure at Aisling Capital, Mr. Schiff built a robust foundation that uniquely positions him in the venture capital world. He began his career in medicine, earning his M.D. from Cornell University Medical College and completing an internal medicine residency at New York Hospital. This clinical background provides him with invaluable insights into unmet medical needs and the scientific rigor required for successful product development. Transitioning to finance, he honed his investment banking skills in the healthcare group at Goldman Sachs, where he gained extensive experience in mergers, acquisitions, and capital markets transactions within the healthcare sector. His academic journey includes a B.A. from Yale University, further solidifying his strong analytical and intellectual capabilities.

Mr. Schiff's career trajectory exemplifies a rare combination of scientific understanding and financial expertise, making him a formidable force in life sciences investing. His work at Aisling Capital continues to drive significant advancements in healthcare, supporting companies that are poised to deliver the next generation of medical breakthroughs. Through his strategic vision and hands-on approach, Andrew Schiff remains a key figure in the venture capital ecosystem, dedicated to funding the innovations that improve global health outcomes.